Objective: To determine the frequency of incidental meningioma and identify associated factors in a population-based sample of participants who systematically underwent brain imaging. Patients and Methods: We searched the Mayo Clinic Study of Aging, a population-based sample of Olmsted County, Minnesota, residents who underwent longitudinal magnetic resonance imaging of the brain. Using a text search of radiologists' notes for 2402 individuals (median age, 75.0 years) who underwent imaging between August 10, 2005, and July 31, 2014, we identified 52 patients (2.2%) who had at least one meningioma. We estimated the association of selected risk factors with the presence of meningioma using odds ratios and 95% CIs from logistic regression models adjusted for age and sex. Based on these results, we moved the most significant variables forward to a multivariable model. Results: Controlling for age and sex, significant associations with the presence of meningioma included higher body mass index (odds ratio [OR], 1.06; 95% CI, 1.01-1.12; P¼.03), nonsteroidal anti-inflammatory drugs (OR, 2.11; 95% CI, 1.13-3.95; P¼.02), aspirin (OR, 1.90; 95% CI, 1.05-3.46; P¼.04), and blood pressureelowering medication (OR, 2.06; 95% CI, 1.06-3.99; P¼.03). Lower risk was associated with male sex (OR, 0.51; 95% CI, 0.29-0.90; P¼.02), coronary artery disease (OR, 0.46; 95% CI, 0.22-0.97; P¼.04), and higher self-reported anxiety (OR, 0.88; 95% CI, 0.78-0.98; P¼.02). Simultaneous adjustment for all of these factors except aspirin in a multivariable model did not attenuate these associations (concordance, 0.71). Conclusion: In a population-based sample of 2402 participants, 52 (2.2%) had an incidental meningioma. They were more likely to be female and have higher body mass index. Meningioma was also associated with certain medications (nonsteroidal anti-inflammatory drugs and blood pressureelowering medications) and inversely with anxiety and coronary artery disease. 
M eningioma is the most common brain tumor, accounting for 36.4% of primary central nervous system tumors. 1 Based on autopsy studies, an estimated 2% of the general population has a meningioma. 2 Many of these tumors are undetected because they are most often slow-growing and over 95% are benign. 3 As such, most clinicians monitor an incidentally discovered meningioma and typically reserve intervention, such as radiosurgery or resection, for cases in which the meningioma poses a clear risk because of size, location, or evidence of progression. 4 Previous epidemiological studies have identified meningioma cases through linkage to medical records, claims databases, or cancer registries, wherein meningiomas were presumably identified clinically. We found just one previous relatively small study that focused on factors associated with incidental meningiomas, 5 in which population-based participants were systematically imaged and 9 incidental meningiomas (1.7%) were found, all in females, but no other associated factors, highlighting the need for more population-based studies. Therefore, we conducted a cross-sectional analysis looking for incidentally identified meningioma and associated factors in a larger sample of participants enrolled in the population-based Mayo Clinic Study of Aging (MCSA) where enrollees systematically undergo brain imaging.
PATIENTS AND METHODS

Study Population and Procedures
All participants were enrolled in the population-based MCSA, a longitudinal study of Olmsted County, Minnesota, residents who were randomly selected from the defined county population for participation in the study. 6 At baseline and approximately every 15 months thereafter, a study coordinator interviewed MCSA participants regarding their family and medical history and an index of subjective cognitive decline, a physician performed a mental status and neurologic examination, and patients completed neuropsychological testing. Participants without a medical contraindication who agreed to undergo imaging underwent 3-T magnetic resonance imaging of the brain at the time of, or soon after, each visit (generally within 3 months). [6] [7] [8] Mayo Clinic neuroradiologists interpreted all magnetic resonance images and entered the findings in the patient record. We completed a text search of the radiologists' notes for the 2402 MCSA individuals scanned between August 10, 2005, and July 31, 2014, using the search terms meningioma, neoplasm, brain lesion, tumor, intracranial tumor, intracranial mass, intracranial lesion, cystic mass, cyst, extra-axial, and dural based. Of the 1050 hits, scans with a "probable" or "possible" meningioma were reviewed, and a radiation oncologist (P.D.B.) verified the determination that a meningioma was present. 9 This process identified 52 of the 2402 participants (2.2%) with at least one meningioma (Figure) .
Factors potentially associated with meningiomas that were ascertained for MCSA participants were analyzed. In selecting variables from the MCSA to examine, we chose those that were found significant in previous meningioma studies, examined in previous studies with insufficient sample size, or theoretically of interest. We also included medical diagnoses and medications that are common, while leaving out a smaller number of variables in which a relationship would seem remote (eg, macular degeneration) or redundant (eg, we chose coronary artery disease [CAD] a blood draw, self-reported cognition, 10 and score on the Short Test of Mental Status 11 from the physician evaluation. Medical diagnoses (CAD, diabetes, hypertension, stroke, dyslipidemia, cancer) and history of head trauma causing memory loss or loss of consciousness were abstracted from the participant medical records. In addition, current medications at the time of the visit (includes total number of medications as well as oral diabetes agents, insulin, statins, blood pressure [BP]elowering medications, medications used for chronic heart failure, warfarin, nonsteroidal anti-inflammatory drugs [NSAIDs; including aspirin], aspirin, selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors combined, tricyclics, multivitamin use, and use of hormone replacement therapies [HRT]-estrogen, HRT-progesterone]) were obtained by self-report at each visit, as was history of ever smoking. The presence of depressive symptoms and anxiety was obtained by self-report using the Beck Depression Inventory-II 12 and the Beck Anxiety Inventory, 13 respectively.
Standard Protocol Approvals and Consents
The Mayo Clinic and Olmsted Medical Center institutional review boards approved all the study protocols, which included review of data collected as part of the MCSA. All participants provided written informed consent. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Statistical Analyses
The 52 cases with meningioma found on imaging were compared to the 2350 individuals without a meningioma on several covariates available in the MCSA. First, we created the list of variables of interest described previously. Characteristics of interest were analyzed for association with meningiomas using the c 2 test or Fisher exact test for categorical data and by the Kruskal-Wallis test for continuous data. Next, we estimated the association of the selected variables with the presence of meningioma using univariate logistic regression models estimating odds ratios (ORs) and 95% CIs and in models adjusted for age and sex. Variables significantly associated with meningioma (P<.05) from age-and sex-adjusted models were then examined simultaneously in a multivariable logistic regression model. Statistical analyses were completed using SAS statistical software, version 9.4 (SAS Institute). Table 3 ). The concordance for the multivariable model was 0.71.
DISCUSSION
Meningioma was identified in 2.2% of participants in our population-based sample of mostly older adults from Olmsted County, Minnesota. This finding is very similar to the 1.7% reported in the only other study examining factors associated with incidental meningioma in a population-based sample that was systematically imaged. 5 The prevalence of meningioma in women in the 2 studies was nearly identical (2.90% in our study and 2.86% in the study by Krampla et al 5 ). Age is a known risk factor for meningioma 4 but was not significantly associated with meningioma in our relatively older sample in whom the median age was 75.6 years and the 25th percentile was 71.0 years. All participants in the Krampla study were aged 75 years, so a relationship with age was not examined. Vernooij et al 14 systematically imaged 2000 individuals in a populationbased sample that was somewhat younger and found a meningioma rate of 0.5% in 45-to 59-year-olds and 1.6% in those 75 years or older. Vernooij et al did not report their meningioma findings by sex or other associated factors.
Body mass index has emerged as a consistent finding in this and other studies 15 and is a potentially modifiable risk factor. Some studies have reported height as an independent risk factor separate from weight, 16 and a large prospective population study in Norway 17 found height but not weight to be associated with meningioma. In contrast, weight was more strongly associated with meningioma than height in both men and women in our study.
Given the consistent finding of BMI and female sex as risk factors for meningioma, there has been a great deal of interest in examining possible associations with metabolic and hormone-related variables in development of this tumor. Findings have been mixed with regard to any elevated risk for women receiving HRT. 18, 19 We did not find a relationship between meningioma and current HRT use, but dosage, duration of use, or any past treatment were not available. The percentage of women taking estrogen in our meningioma group was greater than that in the no meningioma group (12.1% vs 7.1%), but the numbers were extremely small. Johnson et al 16 investigated numerous hormonerelated factors including "never" vs "ever" used HRT, parity, and age at menarche in older, mostly white women in the Iowa Women's Health Study cohort. They found no association between these factors and clinically identified meningioma. Instead, they found a significant relationship with uterine fibroids, postulating that insulin resistance and circulating hormones might be shared risk factors.
In spite of the positive association with BMI, there was no association between meningioma and diabetes in our sample. The relationship between metabolic syndrome and meningioma has been of interest and appears to be complex, with some studies actually finding an inverse relationship between hyperglycemia and clinical meningioma development. 20, 21 We found that CAD was associated with lower risk of meningioma, which seems counter to the positive association between meningioma and taking BPlowering medications, raising the question of potentially spurious associations due to small sample size. However, Seliger et al 20 similarly found a significant negative association between history of myocardial infarction and meningioma.
Body mass index is related to many other cancers as well, 22 and this may be a potential mechanism for the association with meningioma. However, we did not find a relationship between meningioma and a history of other cancers in our sample. In fact, a history of cancer was almost twice as frequent in our no meningioma patients relative to those with meningioma (23.9% vs 12.2%), a finding that was close to significance (P¼.06).
The reason for the relationship between use of NSAIDs with aspirin and meningioma in our study is not clear. However, it is conceivable that some of the participants with a meningioma experienced headaches or other meningioma-related symptoms that they were treating with analgesic medications. That said, the meningiomas were mostly extremely small and therefore unlikely to cause clinical symptoms, and the groups did not differ on self-reported cognitive symptoms. Further, we reported previously that there were no group differences in cognitive impairment on neuropsychological testing or diagnosis of dementia or mild cognitive impairment. 9 The reason for the relationship between higher anxiety scores and meningioma is also unclear, but the anxiety scores in both groups were low, with the median for both groups being just 1 point (out of 63 possible, with scores over 10 suggesting clinically important anxiety).
The strengths of our study include the detection of mostly small clinically silent meningiomas in a population-based sample that could differ considerably from those in most other studies in which tumors were identified through clinical databases and were potentially subject to referral or selection bias. We used a cross-sectional study design that allows us to describe associations and to generate hypotheses for future larger prospective studies. Potential limitations of our study include the inability to infer any causal contribution of any of the factors we studied to the development of meningioma. In addition, our patients were older, and development of meningioma in a younger cohort could look different. For example, Johnson et al 16 found that BMI before age 30 was not predictive of meningioma, whereas the relationship of BMI with meningioma after age 30 was significant. We looked at variables collected in the MCSA, a study designed to investigate factors related to mild cognitive impairment and dementia, so factors significantly related to meningioma might not have been included. For example, one often-cited potential risk factor is exposure to ionizing radiation, 23 which we could not investigate. Our meningioma group was relatively small, so some cell sizes were small. As such, we could have failed to examine potentially significant associations in our study. Our participants were predominantly white, and thus our findings may not be generalizable to studies of other races/ethnicities. In fact, there is emerging evidence of a higher incidence of meningioma in black individuals. 24, 25 Finally, given the exploratory nature of the study, we did not correct for multiple comparisons. For this reason, some of the associations identified could be spurious.
CONCLUSION
In this population-based sample, incidental meningioma was identified in 2.2% of participants. Variables associated with meningioma in this study include use of NSAIDs and BP-lowering medications, higher BMI, and being female. Additional large-sample population-based studies are needed to clarify risk factors for the development of meningioma.
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